Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Editas Medicine, Inc.EDIT · Entity 5502 | Chief Medical Officer | February 07, 2018 | February 09, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Editas Medicine, Inc.
Report date February 07, 2018 · Filed February 09, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $36.67 · Expires 2028-02-06 | Direct | 60,000 |
Reported balance
After 2018-02-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-07 · Grant · Acquired 60,000 · Balance 60,000 F1: This option was granted on February 7, 2018 and is scheduled to vest over four years in equal monthly installments beginning on February 7, 2018 through February 7, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on February 7, 2018 and is scheduled to vest over four years in equal monthly installments beginning on February 7, 2018 through February 7, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 07, 2018 Filed Feb 9, 2018 17:24 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $36.67 | $0.00 |
DisclosureSEC source: 0001179110-18-001908 · edgar.xml · derivative · entry 1 Cox Gerald Frank · CIK 0001686130 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2028-02-06 F1 · derivative.exercise_date: This option was granted on February 7, 2018 and is scheduled to vest over four years in equal monthly installments beginning on February 7, 2018 through February 7, 2022. Read SEC document |
| June 02, 2017 Filed Jun 6, 2017 16:12 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | PurchaseCommon Stock | 4,000 | $14.15 | $56,599.60 |
DisclosureSEC source: 0001179110-17-008654 · edgar.xml · nonDerivative · entry 1 Cox Gerald Frank · CIK 0001686130 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
| October 05, 2016 Filed Oct 6, 2016 19:54 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 225,000 | $0.00 Strike: $15.48 | $0.00 |
DisclosureSEC source: 0001179110-16-030578 · edgar.xml · derivative · entry 1 Cox Gerald Frank · CIK 0001686130 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2026-10-04 F1 · derivative.exercise_date: This option was granted on October 5, 2016 and is scheduled to vest over four years with 25% of the shares scheduled to vest on October 3, 2017, and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through October 3, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.